List it or Lose it: The Federal Circuit Weighs in on the Amgen v. Hospira Discovery Dispute
USA - August 11 2017 The Federal Circuit issued its opinion in the Amgen v. Hospira appeal (16-2179) on August 10, 2017, dismissing the appeal for lack of jurisdiction and...
The Ramifications of Leaving the Patent Dance Floor
USA - August 3 2017 While the Supreme Court held in Amgen v. Sandoz that biosimilar applicants cannot be forced with a federal injunction to provide a copy of their...
PTAB Splits on Instituting Challenges to Herceptin Patents
USA - August 2 2017 On July 27th, the PTAB issued institution decisions in five IPRs brought by Hospira challenging four Genentech patents related to Herceptin...
The Amgen v. Sandoz Disclosure Disputes Continue
USA - July 27 2017 A theme emerging in biosimilar litigation is when - and how much - discovery is available to reference product sponsors. The Supreme Court in Amgen...
Pfizer Takes Aim at Herceptin Patent at the PTAB
USA - July 12 2017 Pfizer has shown its muscle in the biosimilars field, purchasing Hospira in 2015 and launching the second biosimilar on the U.S. market, Inflectra...
